Literature DB >> 2050171

CSF baclofen levels after intrathecal administration in severe spasticity.

B Sallerin-Caute1, Y Lazorthes, B Monsarrat, J Cros, R Bastide.   

Abstract

The pharmacokinetic parameters in the CSF of baclofen given to 4 patients as an intrathecal bolus are reported. Considerable inter-individual variability in the parameters was observed. The elimination half-life ranged from 0.9 to 5 h and the clearance from 0.013 to 0.08 l.h-1. In order to optimize treatment, it is suggested that CSF baclofen levels be matched to changes in Hoffman's monosynaptic reflex (H reflex).

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2050171     DOI： 10.1007/bf00265844

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  9 in total

1.  The chemistry and kinetics of Lioresal.

Authors:  J W Faigle; H Keberle
Journal:  Postgrad Med J       Date:  1972-10       Impact factor: 2.401

2.  (-)Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor.

Authors:  N G Bowery; D R Hill; A L Hudson; A Doble; D N Middlemiss; J Shaw; M Turnbull
Journal:  Nature       Date:  1980-01-03       Impact factor: 49.962

3.  Plasma and cerebrospinal fluid levels of baclofen (Lioresal) at optimal therapeutic responses in spastic paresis.

Authors:  E Knutsson; U Lindblom; A Mårtensson
Journal:  J Neurol Sci       Date:  1974-11       Impact factor: 3.181

4.  Characteristics of GABAB receptor binding sites on rat whole brain synaptic membranes.

Authors:  N G Bowery; D R Hill; A L Hudson
Journal:  Br J Pharmacol       Date:  1983-01       Impact factor: 8.739

5.  Long-term intrathecal baclofen infusion for treatment of spasticity.

Authors:  R D Penn; J S Kroin
Journal:  J Neurosurg       Date:  1987-02       Impact factor: 5.115

6.  High-performance liquid chromatographic analysis of baclofen in plasma and urine of man after precolumn extraction and derivatization with o-phthaldialdehyde.

Authors:  E W Wuis; R J Dirks; T B Vree; E van der Kleyn
Journal:  J Chromatogr       Date:  1985-02-08

7.  Chronic intrathecal baclofen administration for control of severe spasticity.

Authors:  Y Lazorthes; B Sallerin-Caute; J C Verdie; R Bastide; J P Carillo
Journal:  J Neurosurg       Date:  1990-03       Impact factor: 5.115

8.  Are baclofen-sensitive GABAB receptors present on primary afferent terminals of the spinal cord?

Authors:  G W Price; G P Wilkin; M J Turnbull; N G Bowery
Journal:  Nature       Date:  1984 Jan 5-11       Impact factor: 49.962

9.  Bicuculline-insensitive GABA receptors on peripheral autonomic nerve terminals.

Authors:  N G Bowery; A Doble; D R Hill; A L Hudson; J S Shaw; M J Turnbull; R Warrington
Journal:  Eur J Pharmacol       Date:  1981-04-24       Impact factor: 4.432
  9 in total
  9 in total

1.  Clinical and neurophysiologic assessment of strength and spasticity during intrathecal baclofen titration in incomplete spinal cord injury: single-subject design.

Authors:  Mark Bowden; Dobrivoje S Stokic
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

2.  Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen.

Authors:  J Dressnandt; B Conrad
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-02       Impact factor: 10.154

3.  Acute overdose of intrathecal baclofen.

Authors:  J Dressnandt; F X Weinzierl; T R Tölle; A Konstanzer; B Conrad
Journal:  J Neurol       Date:  1996-06       Impact factor: 4.849

4.  Dynamic dual-isotope molecular imaging elucidates principles for optimizing intrathecal drug delivery.

Authors:  Daniel A Wolf; Jacob Y Hesterman; Jenna M Sullivan; Kelly D Orcutt; Matthew D Silva; Merryl Lobo; Tyler Wellman; Jack Hoppin; Ajay Verma
Journal:  JCI Insight       Date:  2016-02-25

5.  A pharmacokinetic-pharmacodynamic model for intrathecal baclofen in patients with severe spasticity.

Authors:  H W Heetla; J H Proost; B H Molmans; M J Staal; T van Laar
Journal:  Br J Clin Pharmacol       Date:  2016-01       Impact factor: 4.335

6.  Accidental intoxication with 60 mg intrathecal baclofen: survived.

Authors:  Benjamin Berger; Barbara Vienenkoetter; Mirjam Korporal; Andrea Rocco; Hans-Michael Meinck; Thorsten Steiner
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

7.  Brain pharmacology of intrathecal antisense oligonucleotides revealed through multimodal imaging.

Authors:  Curt Mazur; Berit Powers; Kenneth Zasadny; Jenna M Sullivan; Hemi Dimant; Fredrik Kamme; Jacob Hesterman; John Matson; Michael Oestergaard; Marc Seaman; Robert W Holt; Mohammed Qutaish; Ildiko Polyak; Richard Coelho; Vijay Gottumukkala; Carolynn M Gaut; Marc Berridge; Nazira J Albargothy; Louise Kelly; Roxana O Carare; Jack Hoppin; Holly Kordasiewicz; Eric E Swayze; Ajay Verma
Journal:  JCI Insight       Date:  2019-10-17

Review 8.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

9.  Interaction of ventriculoperitoneal shunt and baclofen pump.

Authors:  Daniel H Fulkerson; Joel C Boaz; Thomas G Luerssen
Journal:  Childs Nerv Syst       Date:  2007-03-16       Impact factor: 1.532
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.